Plandai Biotechnology, Inc. Announces Phytofare(TM) Shows Potential for Treating Many Infectious Diseases

SEATTLE, Aug. 2, 2012 (GLOBE NEWSWIRE) -- Plandai Biotechnology, Inc. (OTCBB:PLPL), a producer of highly bioavailable plant extracts, today announced that research has demonstrated the potential use of its proprietary green tea gallate catechin extract, Phytofare™, for treating a broad spectrum of infectious parasitic and bacterial infections. Multiple studies have demonstrated the effectiveness of the green tea catechins, EGCG and ECG, on blood stages with research published in the US National Library of Medicine pointing to use of glucose in establishing a foothold in parasitic infected humans. Simply put, glucose is the food that parasites need to survive and multiply. A new field of research has opened up focusing on developing glucose and hexose inhibitors—agents that essentially cut off the food supply by preventing the infection from up taking the glucose.

Back to news